


SHORTSTOP-HER2: SHORTENED DURATION OF ADJUVANT THERAPY IN PATIENTS WITH EARLY-STAGE HER2+ BREAST CANCER WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH HER2 BLOCKADE

Eligibility Criteria

- History of clinical tumor category T1c-T3 and clinical nodal category N0-N1 (except cT3N1 tumors, which are NOT eligible) per AJCC 8th edition
- HER2+ by ASCO/CAP guidelines (See Section 3.2.1)
- Pathologic complete response following neoadjuvant therapy
- Age $\geq$ 18 years
- ECOG Performance Status 0-2
- Prior treatment per Section 3.2.4
- Surgery requirements per Section 3.2.5
- Not pregnant and not nursing
- Adequate hepatic, renal and bone marrow function for therapy
- No comorbid conditions per Section 3.2.8.

Schema



The total duration of treatment includes the treatment received prior to A012303 registration. Treatment is to continue for the specified time per protocol, or until unacceptable adverse event. Patients will be followed for 10 years or until death, whichever comes first.

Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.